Japan Approves Four Drugs Of Swiss-Based Novartis
This article was originally published in PharmAsia News
Executive Summary
Japan regulators have approved four drugs made by Switzerland-based Novartis, one each for asthma, blindness, cancer and hypertension. The approved drugs are Xolair (omalizumab) for severe bronchial asthma in adults, Tasigna (nilotinib) for Philadelphia chromosome-positive chronic myeloid leukemia, Lucentis (ranibizumab) for wet age-related macular degeneration and Diovan (valsartan; hydrochlorothiazide) for treating high blood pressure. Macular degeneration afflicts about 20,000 Japanese annually. (Click here for more
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.